• Building next generation RNA

Company update -
October 11

Circio’s management hosted a live webcast on Wednesday 11 October at 10am CEST.

In the webcast, CEO Dr. Erik D. Wiklund and VP and Head of Research Dr. Thomas B. Hansen provided an overview of recent circRNA data and an update on the development strategy.

Class-Leading Clinical Data

  • ONCOS-102 has shown 35 %

    response rate in PD-1 resistant melanoma, which is one of the best published data sets in this immunotherapy-resistant cancer type

CEO Statement

Circular RNA is a powerful new format for RNA therapeutics, and with our differentiated circVec platform we have a unique opportunity to take a leading role in this emerging space. We are rapidly building our technical capabilities to demonstrate the versatility and broad potential of our technology and put Circio in position to capture the significant potential of vector-delivered circRNA.

Circio aims to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives